Insights

Gathering insights about Chroma…

Similar companies to Chroma

Chroma Tech Stack

Media & News

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the “Company”) and the Company's common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's.
Mar 19, 2025 | www.businesswire.com
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol “NAGE” effective at stock market open on Wednesday, March 19, 2025. As part of this transition, the Company will deploy a follow-up announcement with additional updates regarding the name change, rebrand, an.
Mar 13, 2025 | www.businesswire.com
ChromaDex to Present at the 37th Annual Roth Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels will be livestreamed and available at https://wsw.com/webcast/roth50. Additionally, ChromaD.
Mar 11, 2025 | www.businesswire.com
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial performance includes a 37.41% revenue increase, $7.2 million net income, and expanded gross margins, with a significant e-commerce boost. The company faces challenges like supply chain issues, tariff risks, and regulatory uncertainties, which could impact its ambitious growth targets and market position.
Mar 06, 2025 | seekingalpha.com
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financial Officer Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant Bill Dezellem - Tieton Capital Management Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital J.P.
Mar 04, 2025 | seekingalpha.com
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
ChromaDex (CDXC) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
Mar 04, 2025 | www.zacks.com
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter. General and administrative expense decreased $4.4 million, which includes a $3.5 million reversal of previously accrued roy.
Mar 04, 2025 | www.businesswire.com

Chroma's Email Address Formats

Chroma uses at least 1 format(s):

Chroma Email Formats	Example	Percentage
First.Last@chromasports.com	John.Doe@chromasports.com	50%
First.Last@chromasports.com	John.Doe@chromasports.com	50%

Frequently Asked Questions

Where is Chroma's headquarters located?

Chroma's main headquarters is located at Unit 7, Hove Business Park, Fonthill Road Hove, BN3 6HA, GB. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Chroma's stock symbol?

Chroma is a publicly traded company; the company's stock symbol is CDXC.

What is Chroma's official website and social media links?

Chroma's official website is chromasports.com and has social profiles on LinkedIn.

What is Chroma's SIC code NAICS code?

Chroma's SIC code is 7231 - Beauty Shops NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Chroma have currently?

As of October 2025, Chroma has approximately 108 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Head Of Project Management: S. S.Head Of Growth: K. S.Founder, Principal Writer: A. D.. Explore Chroma's employee directory with LeadIQ.

What industry does Chroma belong to?

Chroma operates in the Technology, Information and Internet industry.

What is Chroma's email format?

Chroma's email format typically follows the pattern of First.Last@chromasports.com. Find more Chroma email formats with LeadIQ.

When was Chroma founded?

Chroma was founded in 2007.

Chroma

Technology, Information and InternetUnited Kingdom51-200 Employees

Chroma design, build and manage digital sports products unparalleled in user experience and engagement. 

Our clients include sports rights holders, media companies, brands and bookmakers across the globe.

We're based in London, Brighton and Sydney.